Canadian Customs to levy tariffs on Nycomed

Article

The Canadian Customs and Revenue Agency has decided to assess duties on Nycomed Amersham Imaging’s Omnipaque and Visipaque, according to Nycomed Amersham Canada. The move came after Mallinckrodt Medical alleged in June that Oakville, Ontario-based

The Canadian Customs and Revenue Agency has decided to assess duties on Nycomed Amersham Imaging’s Omnipaque and Visipaque, according to Nycomed Amersham Canada. The move came after Mallinckrodt Medical alleged in June that Oakville, Ontario-based Nycomed Amersham Canada was dumping its products on the Canadian market. On Nov. 15, the Canadian commissioner of customs and revenue extended the period of investigation for the charges, and on Dec. 31, made a preliminary determination that dumping had occurred. Nycomed Amersham Canada plans to contest the decision before the Canadian International Trade Tribunal, according to Jean-Pierre Huot, general manager. The tribunal will hold hearings on the case in March, Huot said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.